-
前列腺癌(prostate carcinoma,PCa)是全世界发病率居第2、病死率居第5的男性恶性肿瘤,每年新发患者约141.4万例,病死患者约37.5万例[1]。在我国,PCa的发病率呈持续上升态势,1998年为3.5/10万,至2008年达11.0/10万,居男性恶性肿瘤发病率的第6位;长三角地区为显著高发区域[2]。D'Amico标准依据血清前列腺特异抗原(prostate specific antigen,PSA)水平、格里森评分(Gleason score,GS)和肿瘤累及范围对PCa患者进行风险分层,不同风险患者的治疗决策及预后迥异[3]。传统影像学检查方法在PCa的风险分层、精确分期、低水平PSA生化复发的诊断等方面效能不足。为了更好地满足临床需要,PET/CT特异性显像剂68Ga 标记的前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)开始应用于PCa的显像,其中以68Ga-PSMA-11最常见。目前,对初诊PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的研究较少,海外的研究主要为基于欧美人群的小样本、单中心的诊断效能研究[4]。本研究初步探究68Ga-PSMA-11 PET/CT的代谢体积参数在不同维度风险分层的初诊PCa患者之间的差异。
-
85例患者的68Ga-PSMA-11 PET/CT显像结果均呈阳性,其中,无转移组46例(54.1%),转移组39例(45.9%)。在转移组中,仅有1个转移灶的患者10例(11.8%),有2~9个转移灶的患者19例(22.4%),有10个及以上转移灶的患者10例(11.8%)。
GS<8分组的患者33例(38.8%),GS≥8分组的患者52例(61.2%)。PSA≤20 ng/mL组的患者34例(40.0%),PSA>20 ng/mL组的患者51例(60.0%)。临床T1~T2期组的患者53例(62.4%),临床T3~T4期组的患者32例(37.6%)。低中风险组患者15例(17.6%),高风险组患者70例(82.4%)。
患者年龄、GS、PSA、临床T分期、风险分层等具体结果见表1。
参数 无转移组(n=46) 转移组(n=39) 年龄( ,岁)$ \bar x \pm s$ 69.1±7.2 69.2±8.5 GS(例) 6分 6 1 7分 16 10 8分 13 14 9分 10 11 10分 1 3 PSA(例) ≤20 ng/mL 29 5 >20 ng/mL 17 34 T分期(例) T2a 19 1 T2b 5 5 T2c 14 9 T3a 1 1 T3b 7 12 T4 0 11 风险分层(例) 低中风险 13 2 高风险 33 37 注:PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;PCa为前列腺癌;GS为格里森评分;PSA为前列腺特异抗原 表 1 85例PCa患者的临床特征与68Ga-PSMA-11 PET/CT 显像的结果
Table 1. Clinical characteristics and 68Ga-prostate specific membrane antigen-11 PET/CT findings of 85 prostate carcinoma patients
-
由表2可知,高风险组SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于低中风险组,且差异均有统计学意义(均P<0.05)。由表3可知,转移组SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于无转移组,且差异均有统计学意义(均P<0.05)。
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 低中风险组(n=15) 4.2(2.2~21.9) 8.4(1.6~22.4) 11.4(1.6~22.4) 27.4(3.2~86.3) 28.6(3.2~86.3) 高风险组(n=70) 13.8(2.3~50.5) 16.5(1.5~218.4) 21.9(1.7~333.9) 146.1(5.1~3822.0) 229.6(5.3~4510.4) Z值 −3.449 −2.438 −3.009 −3.631 −4.242 P值 <0.001 0.015 0.003 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 2 不同风险分层的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 2. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different risk stratification (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 无转移组(n=46) 9.8(2.2~50.5) 10.8(1.6~58.3) 10.8(1.6~58.3) 37.2(3.2~399.3) 37.2(3.2~399.3) 转移组(n=39) 16.2(2.9~40.0) 39.5(1.5~218.4) 58.8(3.5~333.9) 318.4(5.1~3822.0) 628.0(14.7~4510.4) Z值 −2.580 −4.070 −6.301 −4.022 −5.900 P值 0.010 <0.001 <0.001 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 3 不同转移情况的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 3. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different metastasis (median (range))
由表4可知,GS≥8组SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于GS<8组,除PSMA-TV原发外,差异均有统计学意义(均P<0.05)。由表5可知,PSA>20 ng/mL组SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于PSA≤20 ng/mL组,且差异均有统计学意义(均P<0.001)。由表6可知,临床T3~T4期组SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于临床T1~T2期组,且差异均有统计学意义(均P<0.001)。
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) GS<8分组(n=33) 9.9(2.2~26.9) 12.5(1.6~76.4) 14.3(1.6~133.9) 36.3(3.2~1084.9) 36.3(3.2~1573.9) GS≥8分组(n=52) 14.8(2.3~50.5) 16.5(1.5~218.4) 23.9(1.7~333.9) 146.1(5.1~3822.0) 229.6(5.3~4510.4) Z值 −2.390 −1.231 −2.088 −2.074 −2.850 P值 0.017 0.218 0.037 0.038 0.004 注:GS为格里森评分;PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 4 不同GS评分的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 4. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different GSs (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 临床T1~T2分期组(n=53) 9.3(2.2~31.1) 10.7(1.5~218.4) 14.3(1.6~302.2) 32.6(3.2~3288.0) 45.9(3.2~4510.4) 临床T3~T4分期组(n=32) 16.6(3.1~50.5) 34.9(1.9~160.7) 62.3(2.7~333.9) 303.5(9.5~2187.7) 482.1(14.7~2738.8) Z值 −3.629 −3.792 −4.077 −4.508 −4.889 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 6 不同临床T分期的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 6. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients at different clinical T stages (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) PSA≤20 ng/mL组(n=34) 6.4(2.2~50.5) 8.2(1.5~222.4) 10.2(1.6~22.5) 28.0(3.2~318.3) 29.7(3.2~318.3) PSA>20 ng/mL组(n=51) 16.2(2.3~40.0) 24.7(1.7~218.4) 41.4(1.7~333.9) 253.9(7.5~3822.0) 361.5(7.5~4510.4) Z值 −3.948 −5.329 −5.907 −5.544 −6.279 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:PSA为前列腺特异抗原;PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 5 不同PSA水平的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 5. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different PSA levels (median (range))
-
本研究特选取了4例典型PCa患者的68Ga-PSMA-11 PET/CT显像图,这4例患者的全身肿瘤负荷呈增加的趋势(图1~4)。
图 1 前列腺癌中低风险无转移患者的前列腺68Ga-PSMA-11 PET/CT横断面显像图(A)及最大密度投影图(B)
Figure 1. 68Ga-prostate specific membrane antigen-11 PET/CT transverse image of prostate (A) and maximum density projection image (B) in low risk and non-metastatic patient with prostate carcinoma
图 4 前列腺癌高风险多发转移患者的胸、骶椎及附件68Ga-PSMA-11 PET/CT横断面显像图(A、B)、前列腺横断面融合图(C)及最大密度投影图(D)
Figure 4. 68Ga-prostate specific membrane antigen-11 PET/CT images of thoracic, sacral vertebrae and accessories with multiple metastases (A, B), transverse images of prostate (C) and maximum density projection image (D) in high risk patient with multiple metastases of prostate carcinoma
图 2 前列腺癌高风险无转移患者的前列腺68Ga-PSMA-11 PET/CT横断面显像图(A)及最大密度投影图(B)
Figure 2. 68Ga-prostate specific membrane antigen-11 PET/CT transverse image of prostate (A) and maximum density projection image (B) in high risk non-metastatic patient with prostate carcinoma
图 3 前列腺癌高风险寡转移患者的多发胸椎及附件68Ga-PSMA-11 PET/CT横断面显像图(A、B)、前列腺横断面融合图(C)及最大密度投影图(D)
Figure 3. 68Ga-prostate specific membrane antigen-11 PET/CT images of thoracic vertebrae and accessories with 2 metastases (A, B), transverse image of prostate (C) and maximum density projection image (D) in high risk oligometastatic patient with prostate carcinoma
68Ga-PSMA-11 PET/CT代谢体积参数在不同风险分层的初诊前列腺癌患者中的差异研究
Study on the differences of metabolic volume parameters of 68Ga-PSMA-11 PET/CT among risk stratified subgroups in patients with newly diagnosed prostate carcinoma
-
摘要:
目的 探究68Ga-前列腺特异性膜抗原(PSMA)-11 PET/CT代谢体积参数在不同风险分层的初诊前列腺癌(PCa)患者中的差异。 方法 回顾性分析2019年1月至12月于海军军区大学第一附属医院经前列腺活体组织穿刺检查结果确诊后行68Ga-PSMA-11 PET/CT检查的85例未经治疗的PCa患者的影像及临床资料,患者年龄49~88(69.1±7.7)岁。根据是否发生肿瘤转移和美国国立综合癌症网络指南推荐的风险分层将患者分别分为无转移组和转移组、低中风险组和高风险组;以格里森评分(GS)8分为临界值,将患者分为GS<8分组和GS≥ 8分组;以血清前列腺特异抗原(PSA)20 ng/mL为临界值,将患者分为PSA≤20 ng/mL组和PSA>20 ng/mL组;根据临床分期的不同,将患者分为临床T1~T2期组和临床T3~T4期组。采用三维勾画法在68Ga-PMSA-11 PET/CT图像上自动测量和勾画肿瘤病灶感兴趣区,计算最大标准化摄取值(SUVmax)、原发PSMA肿瘤体积(PSMA-TV原发)、全身PSMA肿瘤体积(PSMA-TV全身)、原发PSMA肿瘤总量(TL-PSMA原发)、全身PSMA肿瘤总量(TL-PSMA全身)。组间代谢体积参数的比较采用两独立样本非参数Mann-Whitney秩和检验。 结果 85例患者68Ga-PSMA-11 PET/CT显像结果均呈阳性,其中无转移组46例(54.1%)、转移组39例(45.9%);低中风险组15例(17.6%)、高风险组70例(82.4%)。转移组的SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于无转移组(16.2对9.8,39.5 cm3对10.8 cm3,58.8 cm3对10.8 cm3,318.4 cm3对37.2 cm3,628.0 cm3对37.2 cm3),且差异均有统计学意义(Z=−6.301~−2.580,均P<0.05);高风险组的SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于低中风险组(13.8对4.2,16.5 cm3对8.4 cm3,21.9 cm3对11.4 cm3,146.1 cm3对27.4 cm3,229.6 cm3对28.6 cm3),且差异均有统计学意义(Z=−4.242~−2.438,均P<0.05);GS≥8分组的SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于GS<8分组(14.8对9.9,16.5 cm3对12.5 cm3,23.9 cm3对14.3 cm3,146.1 cm3对36.3 cm3,229.6 cm3对36.3 cm3),除PSMA-TV原发外,差异均有统计学意义(Z=−2.850~−2.074,均P<0.05);PSA>20 ng/mL组的SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于PSA≤20 ng/mL组(16.2对 6.4,24.7 cm3对8.2 cm3,41.4 cm3对10.2 cm3,253.9 cm3对28.0 cm3,361.5 cm3对29.7 cm3),且差异均有统计学意义(Z=−6.279~−3.948,均P<0.001);临床T3~T4期组的SUVmax、PSMA-TV原发、PSMA-TV全身、TL-PSMA原发、TL-PSMA全身的中位数均高于临床T1~T2期组(16.6对9.3,34.9 cm3对10.7 cm3,62.3 cm3对14.3 cm3,303.5 cm3对32.6 cm3,482.1 cm3对45.9 cm3),且差异均有统计学意义(Z=−4.889~−3.629,均P<0.001)。 结论 转移组和高风险组的初诊前列腺癌患者68Ga-PSMA-11 PET/CT的代谢体积参数显著高于无转移组及低中风险组患者。 -
关键词:
- 前列腺肿瘤 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 肿瘤负荷 /
- 前列腺特异性膜抗原 /
- 风险分层 /
- 代谢体积参数
Abstract:Objective To explore significant differences in the metabolic volume parameters of prostate specific membrane antigen labeled with 68Gallium (68Ga-PSMA-11) PET/CT among different risk stratification subgroups in patients with newly diagnosed prostate carcinoma (PCa). Methods The images and clinical data of 85 untreated patients with PCa (aged 49–88 (69.1±7.7) years) newly diagnosed by prostate biopsy and examined by 68Ga-PSMA-11 PET/CT in the First Affiliated Hospital of Naval Military Medical University from January 2019 to December 2019 were analyzed retrospectively. In accordance with the occurrence of tumor metastasis and the risk stratification recommended by the guidelines of National Comprehensive Cancer Network, patients were divided into binary subgroups: non-metastasis and metastasis subgroups as well as low-medium- and high-risk subgroups. Taking the Gleason score (GS)=8 as the critical value, patients were divided into GS<8 and GS≥8 subgroups. Taking serum prostate specific antigen (PSA)=20 ng/mL as the critical value, patients were divided into PSA≤20 ng/mL and PSA>20 ng/mL subgroups. In accordance with clinical stage, patients were divided into clinical T1–T2 and T3–T4 subgroups. Three dimensional sketching method was used to automatically measure and sketch the region of interest of tumor lesions on 68Ga-PSMA-11 PET/CT images, and calculate the maximum standardized uptake value (SUVmax), primary PSMA tumor volume (PSMA-TVprimary), whole-body PSMA tumor volume (PSMA-TVwhole body), total number of primary PSMA tumors (TL-PSMAprimary), and total number of whole-body PSMA tumors (TL-PSMAwhole body) separately. The metabolic volume parameters between subgroups were compared by the nonparametric Mann-Whitney U rank sum test of two independent samples. Results The results of 68Ga-PSMA-11 PET/CT were positive in all 85 patients, including 46 cases (54.1%) in the non-metastasis subgroup and 39 cases (45.9%) in the metastasis subgroup as well as 15 cases (17.6%) in the low-medium-risk subgroup and 70 cases (82.4%) in the high-risk subgroup. The SUVmax, PSMA-TVprimary, PSMA-TVwhole body, TL-PSMAprimary, and TL-PSMAwhole body in the metastasis subgroup were significantly higher than those in the non-metastasis subgroup (16.2 vs. 9.8, 39.5 cm3 vs. 10.8 cm3, 58.8 cm3 vs. 10.8 cm3, 318.4 cm3 vs. 37.2 cm3, 628.0 cm3 vs. 37.2 cm3; Z=−6.301 to −2.580, all P<0.05). The SUVmax, PSMA-TVprimary, PSMA-TVwhole body, TL-PSMAprimary, and TL-PSMAwhole body in the high-risk subgroup were significantly higher than those in the low-medium-risk subgroup (13.8 vs. 4.2, 16.5 cm3 vs. 8.4 cm3, 21.9 cm3 vs. 11.4 cm3, 146.1 cm3 vs. 27.4 cm3, 229.6 cm3 vs. 28.6 cm3; Z=−4.242 to −2.438, all P<0.05). The SUVmax, PSMA-TVwhole body, TL-PSMAprimary, and TL-PSMAwhole body in the GS≥8 subgroup were significantly higher than those in the GS<8 subgroup (14.8 vs. 9.9, 23.9 cm3 vs. 14.3 cm3, 146.1 cm3 vs. 36.3 cm3, 229.6 cm3 vs. 36.3 cm3; Z=−2.850 to −2.074, all P<0.05), whereas the PSMA-TVprimary was not significantly different between the two subgroups (16.5 cm3 vs. 12.5 cm3, Z=−1.231, P=0.218). The SUVmax, PSMA-TVprimary, PSMA-TVwhole body, TL-PSMAprimary, and TL-PSMAwhole body in the PSA>20 ng/mL subgroup were significantly higher than those in the PSA≤20 ng/mL subgroup (16.2 vs. 6.4, 24.7 cm3 vs. 8.2 cm3, 41.4 cm3 vs. 10.2 cm3, 253.9 cm3 vs. 28.0 cm3, 361.5 cm3 vs. 29.7 cm3; Z=−6.279 to −3.948, all P<0.001). The SUVmax, PSMA-TVprimary, PSMA-TVwhole body, TL-PSMAprimary, and TL-PSMAwhole body in the clinical T3–T4 subgroup were significantly higher than those in the clinical T1–T2 subgroup (16.6 vs. 9.3, 34.9 cm3 vs. 10.7 cm3, 62.3 cm3 vs. 14.3 cm3, 303.5 cm3 vs. 32.6 cm3, 482.1 cm3 vs. 45.9 cm3; Z=−4.889 to −3.629, all P<0.001). Conclusion The metabolic volume parameters based on 68Ga-PSMA-11 PET/CT in metastatic and high-risk patients with newly diagnosed PCa were significantly higher than those in non-metastatic and low-medium-risk patients. -
图 4 前列腺癌高风险多发转移患者的胸、骶椎及附件68Ga-PSMA-11 PET/CT横断面显像图(A、B)、前列腺横断面融合图(C)及最大密度投影图(D)
Figure 4. 68Ga-prostate specific membrane antigen-11 PET/CT images of thoracic, sacral vertebrae and accessories with multiple metastases (A, B), transverse images of prostate (C) and maximum density projection image (D) in high risk patient with multiple metastases of prostate carcinoma
图 3 前列腺癌高风险寡转移患者的多发胸椎及附件68Ga-PSMA-11 PET/CT横断面显像图(A、B)、前列腺横断面融合图(C)及最大密度投影图(D)
Figure 3. 68Ga-prostate specific membrane antigen-11 PET/CT images of thoracic vertebrae and accessories with 2 metastases (A, B), transverse image of prostate (C) and maximum density projection image (D) in high risk oligometastatic patient with prostate carcinoma
表 1 85例PCa患者的临床特征与68Ga-PSMA-11 PET/CT 显像的结果
Table 1. Clinical characteristics and 68Ga-prostate specific membrane antigen-11 PET/CT findings of 85 prostate carcinoma patients
参数 无转移组(n=46) 转移组(n=39) 年龄( ,岁)$ \bar x \pm s$ 69.1±7.2 69.2±8.5 GS(例) 6分 6 1 7分 16 10 8分 13 14 9分 10 11 10分 1 3 PSA(例) ≤20 ng/mL 29 5 >20 ng/mL 17 34 T分期(例) T2a 19 1 T2b 5 5 T2c 14 9 T3a 1 1 T3b 7 12 T4 0 11 风险分层(例) 低中风险 13 2 高风险 33 37 注:PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;PCa为前列腺癌;GS为格里森评分;PSA为前列腺特异抗原 表 2 不同风险分层的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 2. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different risk stratification (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 低中风险组(n=15) 4.2(2.2~21.9) 8.4(1.6~22.4) 11.4(1.6~22.4) 27.4(3.2~86.3) 28.6(3.2~86.3) 高风险组(n=70) 13.8(2.3~50.5) 16.5(1.5~218.4) 21.9(1.7~333.9) 146.1(5.1~3822.0) 229.6(5.3~4510.4) Z值 −3.449 −2.438 −3.009 −3.631 −4.242 P值 <0.001 0.015 0.003 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 3 不同转移情况的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 3. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different metastasis (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 无转移组(n=46) 9.8(2.2~50.5) 10.8(1.6~58.3) 10.8(1.6~58.3) 37.2(3.2~399.3) 37.2(3.2~399.3) 转移组(n=39) 16.2(2.9~40.0) 39.5(1.5~218.4) 58.8(3.5~333.9) 318.4(5.1~3822.0) 628.0(14.7~4510.4) Z值 −2.580 −4.070 −6.301 −4.022 −5.900 P值 0.010 <0.001 <0.001 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 4 不同GS评分的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 4. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different GSs (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) GS<8分组(n=33) 9.9(2.2~26.9) 12.5(1.6~76.4) 14.3(1.6~133.9) 36.3(3.2~1084.9) 36.3(3.2~1573.9) GS≥8分组(n=52) 14.8(2.3~50.5) 16.5(1.5~218.4) 23.9(1.7~333.9) 146.1(5.1~3822.0) 229.6(5.3~4510.4) Z值 −2.390 −1.231 −2.088 −2.074 −2.850 P值 0.017 0.218 0.037 0.038 0.004 注:GS为格里森评分;PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 6 不同临床T分期的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 6. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients at different clinical T stages (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) 临床T1~T2分期组(n=53) 9.3(2.2~31.1) 10.7(1.5~218.4) 14.3(1.6~302.2) 32.6(3.2~3288.0) 45.9(3.2~4510.4) 临床T3~T4分期组(n=32) 16.6(3.1~50.5) 34.9(1.9~160.7) 62.3(2.7~333.9) 303.5(9.5~2187.7) 482.1(14.7~2738.8) Z值 −3.629 −3.792 −4.077 −4.508 −4.889 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 表 5 不同PSA水平的PCa患者68Ga-PSMA-11 PET/CT代谢体积参数的差异比较[中位数(范围)]
Table 5. Comparison of metabolic volume parameters of 68Ga-prostate specific membrane antigen-11 PET/CT in prostate carcinoma patients with different PSA levels (median (range))
组别 SUVmax PSMA-TV原发(cm3) PSMA-TV全身(cm3) TL-PSMA原发(cm3) TL-PSMA全身(cm3) PSA≤20 ng/mL组(n=34) 6.4(2.2~50.5) 8.2(1.5~222.4) 10.2(1.6~22.5) 28.0(3.2~318.3) 29.7(3.2~318.3) PSA>20 ng/mL组(n=51) 16.2(2.3~40.0) 24.7(1.7~218.4) 41.4(1.7~333.9) 253.9(7.5~3822.0) 361.5(7.5~4510.4) Z值 −3.948 −5.329 −5.907 −5.544 −6.279 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:PSA为前列腺特异抗原;PCa为前列腺癌;PSMA为前列腺特异性膜抗原;PET/CT为正电子发射断层显像计算机体层摄影术;SUVmax为最大标准化摄取值;TV为肿瘤体积;TL为肿瘤总量 -
[1] Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209−249. DOI: 10.3322/caac.21660. [2] 叶定伟, 朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249−252. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.003.
Ye DW, Zhu Y. Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249−252. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.003.[3] Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(5): 479−505. DOI: 10.6004/jnccn.2019.0023. [4] Satapathy S, Singh H, Kumar R, et al. Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis[J]. AJR Am J Roentgenol, 2021, 216(3): 599−607. DOI: 10.2214/AJR.20.23912. [5] Brito AET, Mourato FA, de Oliveira RPM, et al. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer[J]. Ann Nucl Med, 2019, 33(5): 344−350. DOI: 10.1007/s12149-019-01342-z. [6] Demirci E, Kabasakal L, Şahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?[J]. Nucl Med Commun, 2019, 40(1): 86−91. DOI: 10.1097/MNM.0000000000000942. [7] Basha MAA, Hamed MAG, Hussein O, et al. 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement[J]. Abdom Radiol (NY), 2019, 44(7): 2545−2556. DOI: 10.1007/s00261-019-02006-2. [8] Meyrick DP, Asokendaran M, Skelly LA, et al. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer[J]. Nucl Med Commun, 2017, 38(11): 956−963. DOI: 10.1097/MNM.0000000000000738. [9] Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6): 941−949. DOI: 10.1007/s00259-017-3631-6. [10] Ergül N, Burçak YG, Yücetaş U, et al. 68Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma[J]. Clin Nucl Med, 2018, 43(12): e422−e427. DOI: 10.1097/RLU.0000000000002289. [11] Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer[J]. J Nucl Med, 2017, 58(12): 1962−1968. DOI: 10.2967/jnumed.117.193581. [12] Schmidkonz C, Cordes M, Schmidt D, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1862−1872. DOI: 10.1007/s00259-018-4042-z. [13] Etchebehere EC, Araujo JC, Fox PS, et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival[J]. J Nucl Med, 2015, 56(8): 1177−1184. DOI: 10.2967/jnumed.115.158626. [14] Liu C, Liu TL, Zhang N, et al. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1852−1861. DOI: 10.1007/s00259-018-4037-9. [15] Kuroda K, He L. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor[J]. Int J Oncol, 2019, 54(4): 1357−1366. DOI: 10.3892/ijo.2019.4706. [16] von Eyben FE, Picchio M, von Eyben R, et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis[J/OL]. Eur Urol Focus, 2018, 4(5): 686−693[2020-09-01]. https://www.eu-focus.europeanurology.com/article/S2405-4569(16)30160-2/fulltext. DOI: 10.1016/j.euf.2016.11.002. [17] Koerber SA, Utzinger MT, Kratochwil C, et al. 68Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters[J]. J Nucl Med, 2017, 58(12): 1943−1948. DOI: 10.2967/jnumed.117.190314. [18] Ruigrok EAM, van Weerden WM, Nonnekens J, et al. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research[J/OL]. Pharmaceutics, 2019, 11(11): 560[2020-09-01]. https://www.mdpi.com/1999-4923/11/11/560. DOI: 10.3390/pharmaceutics11110560. [19] Schollhammer R, De Clermont Gallerande H, Yacoub M, et al. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples[J/OL]. EJNMMI Res, 2019, 9(1): 52[2020-09-01]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-019-0517-6. DOI: 10.1186/s13550-019-0517-6. [20] Fankhauser CD, Poyet C, Kroeze SGC, et al. Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer[J]. World J Urol, 2019, 37(3): 457−467. DOI: 10.1007/s00345-018-2408-2.